



I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: August 14, 2007

Signature: 

Christine Shayda

Docket No.: 0112418.00151US2/  
AUR-016US  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Elias GEORGES et al.	Confirmation No.:	2507
Application No.:	10/801,988	Art Unit:	1642
Filed:	March 15, 2004	Examiner:	C. Joyce
Title:	TRIOSEPHOSPHATE ISOMERASE DIRECTED DIAGNOSTICS AND THERAPEUTICS FOR MULTIDRUG RESISTANT NEOPLASTIC DISEASE		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Dear Sir:

This Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. No fee is required.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.


Application No.: 10/801,988

Docket No.: 0112418.00151US2/AUR-016US

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 08-0219, under Order No. 0112418.00151US2 from which the undersigned is authorized to draw.

Respectfully submitted,

Dated: August 14, 2007



Ann-Louise Kerner, Ph.D.

Registration No.: 33,523

Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP  
60 State Street  
Boston, Massachusetts 02109  
(617) 526-6000 (telephone)  
(617) 526-5000 (facsimile)



Used in Lieu of PTO/SB/08A/B  
(Based on PTO 04-07 version)

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/801,988-Conf. #2507
				Filing Date	March 15, 2004
				First Named Inventor	Elias GEORGES
				Art Unit	1642
				Examiner Name	C. Joyce
Sheet	1	of	1	Attorney Docket Number	0112418.00151US2/AUR-016US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	AEBI, Stefan et al. July 1, 1996. "Loss of DNA Mismatch Repair in Acquired Resistance to Cisplatin." <i>Cancer Research</i> . 56, 3087-3090.	
	CB	DUAN, Zhenfeng et al. November 1999. "Discovery of Differentially Expressed Genes Associated with Paclitaxel Resistance Using cDNA Array Technology: Analysis of Interleukin (IL) 6, IL-8, and Monocyte Chemotactic Protein 1 in the Paclitaxel-resistant Phenotype." <i>Clinical Cancer Research</i> . Vol. 5, 3445-3453.	
	CC	HUSAIN, Amreen et al. March 15, 1998. "BRCA1 Up-Regulation Is Associated with Repair-mediated Resistance to cis-Diamminedichloroplatinum(II)." <i>Cancer Research</i> . 58, 1120-1123.	
	CD	LANGTON-WEBSTER, Beatrice C. et al. December 1994. "Development of Resistance to Cisplatin Is Associated with Decreased Expression of the gp185c-erbB-2 Protein and Alterations in Growth Properties and Responses to Therapy in an Ovarian Tumor Cell Line." <i>Cell Growth &amp; Differentiation</i> . Vol. 5, 1367-1372.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

6322474

US1DOCS 6322474v1